1074. Regional differences in CLABSI prevention: Results of the pan-European PROHIBIT Survey
Session: Poster Abstract Session: Surveillance of HAIs: Evaluating National Strategy
Friday, October 4, 2013
Room: The Moscone Center: Poster Hall C
Background:

The PROHIBIT “Prevention of Hospital Infections by Intervention and Training” survey was initiated to obtain data on practices on healthcare associated infection (HAI) prevention and to identify enabling factors or barriers to compliance with evidence-based recommendations. Stratified data on central line associated bloodstream infection (CLABSI) prevention will be presented for Europe.

Methods:

A questionnaire examining the implementation of national guidelines on HAI prevention in European hospitals was sent to national contact points (NCPs). NCPs invited national hospitals for participation between 09/2011 and 03/2012. Questions regarding CLABSI prevention were answered by the local leading nurse. Countries were stratified according to the United Nations’ regional grouping.

Results:

24 countries submitted data from 397 intensive care units (ICUs) of 308 hospitals. Hospitals were grouped into: Western (n=64), Northern (n= 73), Southern (n= 83) and Eastern European region (n= 88). ICUs had in median 9 beds [6; 12]. The majority of ICUs had local written policies for CL insertion (90%) and care (87%).

Table 1: Percentages of ICUs performing specific CLABSI prevention measures in Europe

 

Eastern Europe

Northern Europe

Southern Europe

Western Europe

Antiseptic for skin disinfection before CL insertion

  • Alcohol-based chlorhexidine 0.5%

7

9

10

24

  • Alcohol-based chlorhexidine 2%

6

49

47

5

  • Non-alcoholic chlorhexidine 2%

0

1

11

0

  • Alcohol-based iodine

20

5

11

15

  • Non-alcoholic iodine

40

1

11

3

  • Alcohol-based octenidine

0

0

0

10

  • Non-alcoholic octenidine

1

0

1

3

  • Alcohol

23

26

5

31

Preferred CL insertion site

  • Subclavian vein

65

37

63

38

  • Jugular vein

26

59

27

49

Replacement of administration sets for aqueous solution

  • < 24 hours

63

34

19

16

  • 24 – 48 hours

29

14

25

12

  • 49 – 72 hours

8

47

43

53

  • 73 - 96 hours

0

4

13

15

  • > 96 hours

0

0

1

4

Conclusion:

Data on CLABSI prevention shows a huge variability across Europe. Prevention measures are not fully implemented. Since participation was based on hospitals' interest, data are not fully representative for Europe. Further analysis will identify organizational characteristics which have a benefit on infection control performance.

Sonja Hansen, MD, MPH1, Frank Schwab, PhD2, Michael Behnke, PhD2, Walter Zingg, MD3, Didier Pittet, MD, MS3, Petra Gastmeier, MD1 and PROHIBIT Consortium, (1)Institute of Hygiene and Environmental Medicine, Charité – University Medicine Berlin, Berlin, Germany, (2)German National Reference Center for the Surveillance of Nosocomial Infections, Berlin, Germany, (3)Infection Control Programme, University of Geneva Hospitals, Geneva, Switzerland

Disclosures:

S. Hansen, None

F. Schwab, None

M. Behnke, None

W. Zingg, None

D. Pittet, None

P. Gastmeier, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.